Trial intelligence / Profile preview

BMS-708163 in Mild to Moderate Alzheimer's Disease

2008-005929-11Phase 2Completed

Sponsor
Bristol Myers Squibb
Start
Dec 2008
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing BMS-708163 with Placebo (2 arms). Primary endpoint: Safety and tolerability of BMS-708163. Started Dec 2008; status: completed.

02

Drugs

avagacestat
03

Conditions

Alzheimer's disease (AD)

Beyond the preview

Go deeper on 2008-005929-11.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-005929-11.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call